A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci

Academic Article


  • Current polysaccharide-based pneumococcal vaccines are effective but not compatible with all serotypes of Streptococcus pneumoniae. We previously developed an adjuvant-free cationic nanogel nasal vaccine containing pneumococcal surface protein A (PspA), which is expressed on the surfaces of all pneumococcal serotypes. Here, to address the sequence diversity of PspA proteins, we formulated a cationic nanogel-based trivalent pneumococcal nasal vaccine and demonstrated the vaccine's immunogenicity and protective efficacy in macaques by using a newly developed nasal spray device applicable to humans. Nasal vaccination of macaques with cationic cholesteryl pullulan nanogel (cCHP)-trivalent PspA vaccine effectively induced PspA-specific IgGs that bound to pneumococcal surfaces and triggered complement C3 deposition. The immunized macaques were protected from pneumococcal intratracheal challenge through both inhibition of lung inflammation and a dramatic reduction in the numbers of bacteria in the lungs. These results demonstrated that the cCHP-trivalent PspA vaccine is an effective candidate vaccine against pneumococcal infections.
  • Authors

    Published In

  • Vaccine  Journal
  • Digital Object Identifier (doi)

    Pubmed Id

  • 24802062
  • Author List

  • Nakahashi-Ouchida R; Uchida Y; Yuki Y; Katakai Y; Yamanoue T; Ogawa H; Munesue Y; Nakano N; Hanari K; Miyazaki T
  • Start Page

  • 3353
  • End Page

  • 3364
  • Volume

  • 39
  • Issue

  • 25